SPL.ASX: Fully Underwritten Entitlement Offer to Raise $32 Million

Fully Underwritten Entitlement Offer to Raise $32 Million

Stock	Starpharma Holdings Ltd (SPL.ASX)
Release Time	15 Jul 2026, 9:10 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

Starpharma Announces $32M Capital Raise for Oncology Development

Key Points

Fully underwritten entitlement offer to raise $32M
Offer price at $0.57 per share, 25% discount to last closing price
Proceeds to extend cash runway into FY28

Full Summary

Starpharma Holdings Ltd, an innovative biotechnology company, announced a fully underwritten renounceable entitlement offer to raise approximately $32 million. The offer will issue approximately 56 million new ordinary shares at an issue price of $0.57, representing a 25% discount to the last ASX traded closing price. The proceeds will strengthen the company's balance sheet, extend its cash runway into FY28, and support the progression of the DEP® HER2-Lu Phase 1 study and the development of novel dendrimer-based oncology assets. The offer is open to eligible shareholders on a one for seven and a half (7.5) pro rata basis, with the offer price representing a 22% discount to the Theoretical Ex Rights Price (TERP) of $0.73.

Guidance

Proceeds expected to extend cash runway into FY28, supporting oncology development

Outlook

The company aims to leverage the raised capital to accelerate the development of its dendrimer-based oncology assets, with a focus on extending its cash runway into FY28.